The Board of Pharmacy has received notice of the following product recall:

Aurobindo Pharma USA has initiated a recall to the retail level of the following Ranitidine containing products:

Product Name	NDC	Batch Number	Exp. Date
Ranitidine Tablets 150mg	55910-092-79	NBSB1900lDA3	Feb-2021
Ranitidine Capsules 150mg	59651-144-60	RAl518001-A	Jul-2020
		RA1518002-A	Jul-2020
	59651-144-05	RA1518002-B	Jul-2020
		RA1518003-A	Jul-2020
		RA1518004-A	Aug-2020
		RAl5l8005-A	Aug-2020
	59651-144-60	RA1518005-B	Aug-2020
		RA1518006-A	Aug-2020
	59651-144-05	RA1518007-A	Sep 2020
		RA1518008-A	Sep 2020
		RA1518009-A	Sep 2020
		RA1518010-A	Oct 2020
		RA151801 l-A	Nov2020
		RAl518012-A	Nov2020
		RAl518013-A	Nov2020
		RA1518014-A	Nov2020
		RAl5l80l5-A	Nov2020
	59651-144-60	RA1519003-A	May-2021
	59651-144-05	RAl519003-B	May 2021
		RAl519004-A	May 2021
Ranitidine Capsules 300mg	59651-145-30	RA3018001-A	Jul-2020
		RA30l8002-A	Jul-2020
		RA3018003-A	Jul-2020
		RA30l8004-A	Aug-2020
		RA3018005-A	Aug-2020
		RA3018006-A	Aug-2020
		RA3018007-A	Sep-2020
		RA3018008-A	Sep-2020

Product Name	NDC	Batch Number	Exp. Date
Ranitidine Capsules 300mg	59651-145-30	RA3018009-A	Sep-2020
		RA3018010-A	Oct-2020
		RA3019001-A	Jan 2021
		RA3019002-A	Jan 2021
		RA3019003-A	May-2021
Ranitidine Syrup (Ranitidine Oral Solution, USP) 15 mg/mL (75 mg/5 mL)	65862-431-74	Uil5l9001-A	May-2021
		UI1519002-A	May-2021
		Ull519003-A	May-2021
		Ull 519004-A	May-2021

These lots are being recalled due to the detection of unexpected impurity in the testing of the drug product batches. Aurobindo began shipping these batches to customers nationwide from 28 September 2018 through 19 September 2019.

The Board of Pharmacy strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.